Cardiac surgery is being performed in patients with increasing age and comorbidity. Despite extensive evidence of benefit in selected patients 1 , cardiac operations are high-cost endeavours with limited evidence of survival benefit in some patient cohorts. In contrast, there is robust evidence of a range of potential harms, including serious long-term postoperative disability [2] [3] [4] . Patients who are more frail, as reflected in indices such as the EuroSCORE or Charlson Comorbidity Index are known to have higher rates of complications, longer intensive care unit stays and more long-term adverse sequelae from surgery 5 . With growing technical capacity to support patients of increasing frailty, this therapeutic option is not infrequently used, despite limited evidence as to outcomes in this high-risk group. In an era in which the increasing costs of healthcare are unsustainable, and gains in life expectancy may potentially be gains only in duration of infirmity rather than preservation of health, tools such as economic analysis force us to reflect on the value of the interventions we provide. We are now increasingly being called on to contemplate how health resources are best directed. As clinicians, our obligations to the community force us to consider and debate boundaries as to how therapies are offered.
In this issue, Ho 6 presents an analysis of the health service costs of cardiac surgery in a substantial cohort of patients who received operations in an Australian centre. The striking finding, which bears out other work in the field 7, 8, 9 , is that well-established preoperative assessment tools can identify the cohort with higher cost per year of survival after surgery (although perhaps not individual patients). The other key finding is that the same cohort has greater hospital stay and resource use and, importantly, shorter survival.
A strength of the paper is the detail with which the costing of procedures has been done, and the figures generated are real-world and relevant. Another strength is the simplicity and robustness of the actuarial data underlying the analysis. An important weakness, acknowledged by the author, is that all survival after the operation is attributed to the operation; another is that life expectancy is based on average life expectancy rather than life expectancy for a survivor at the age of operation. For these reasons, the work, though well-conducted and with clear outcomes, should be seen as exploratory, and if there is an error it will most likely be in underestimating cost per year of life after surgery.
An issue that needs to be considered in evaluating this work, or the cost-effectiveness of procedures in general, is the cut-off of 'value for money' of health service cost per unadjusted life-year. In the study reported by Ho, a cost figure of A$100,000 per year of life after surgery was exceeded in 8% of the study cohort. A wide range of values has been used to describe the maximal cost per life-year gained that can be justified by a society, and there are clearly subjective elements to this 10 and emotive issues that are outside the scope of this editorial. Nevertheless, the annual cost of in-unit haemodialysis has been used as a 'benchmark' by some authors in this field, which currently in Australia is estimated to be about A$79,000 per annum 11 . For this reason, some may argue that costs >A$100,000 per year of life after cardiac surgery would be a generous choice of 'value for money'. The World Health Organization figure of three times median income does, however, make the A$100,000 appear appropriate or even conservative 12 .
Quality of survival is not addressed in Ho's dataset, and, though this is not an endpoint of the study, it does bear on the topic at hand. Only about half of the patients having coronary artery bypass surgery report improved quality of life at one year postoperatively 13 . Higher risk patients not only cost more to look after perioperatively, but also have lower indices of health postoperatively 14, 15 . Given that, even in the setting of high-risk coronary disease, life expectancy prolongation is in the order of four to 14 months 16 , the cost and burden of care need to be weighed up against these facts.
Ho's paper presents a strong, albeit preliminary, signal that there is a cohort of patients receiving cardiac surgery for whom higher costs, and possibly cost-ineffectiveness, can be predicted on a population basis. This is a small but significant subset (8%) of patients, even using a model that probably overestimates cost-effectiveness. The EuroSCORE and Charlson Comorbidity Index were both correlated with outcomes in this study (perhaps unsurprisingly as there is some commonality in their data); the former is routinely collected on prospective cardiac surgical candidates and is already used to inform aspects of surgical decision-making. That this is the cohort with higher preoperative predictive scores for adverse outcomes will be of no surprise to those who look after such patients. The elephant in the room is whether we should (or even can) take selection for cardiac surgery a step further from the level of predicting risk of death, to the level of risk of adverse outcome and likely costs, and using these to inform our decisions.
Given the substantial resources that go into cardiac surgery at a national level, the questions that the paper raises are important, need answering at a broader level than the anaesthetic and intensive care communities and call for detailed study of cost-effectiveness in cardiac procedures, coupled to patient-centred outcomes. Armed with such information, clinicians and communities could hopefully make more informed decisions about the future selection of patients for these procedures. Ho is to be applauded for making a valuable contribution to inform current and future discussion in this area.
On a broader note, this paper also raises the issue of resource allocation and patient harm versus good in caring for patients for whom a complex, high-risk and expensive intervention results in a high probability of significant suffering and poor health outcome and a low probability of being restored to good health. This is a looming crisis and indeed one that many regard as already well upon us. As clinicians and citizens, we need to engage the community to ask whether there is a difference between what we can do and what we should do.
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